Inspira™ Preparing Production in Response to Spread of Respiratory Virus in China
Inspira Technologies' Production Plans: Inspira Technologies is preparing for a potential increase in production of its INSPIRA™ ART100 respiratory device due to the recent outbreak of human metapneumovirus (hMPV) in China, indicating a growing global demand for advanced respiratory care technologies.
Innovative Medical Technology: The INSPIRA™ ART100 device aims to revolutionize mechanical ventilation by providing an alternative that stabilizes oxygen levels without requiring patients to be on ventilators, and has recently received FDA clearance for specific medical procedures.
Trade with 70% Backtested Accuracy
Analyst Views on IINNW

No data
About the author

Production Scale-Up: Inspira Technologies has increased production of its INSPIRA ART100 system in anticipation of demand from a European governmental authority, with negotiations nearing finalization.
Market Adoption: The ART100 system is gaining recognition as a reliable device for critical care and emergency preparedness, having already been implemented in clinical settings in the U.S.

Inspira Technologies Deployment: Inspira Technologies has delivered its INSPIRA™ ART100 respiratory support systems to Glo-Med Networks for deployment in a leading U.S. hospital, aiming to enhance patient care with innovative life-support technology and direct support from their team.
Innovative Medical Technology: The INSPIRA™ ART100 system is designed to revolutionize cardiopulmonary bypass procedures and is set to be integrated with the HYLA™ blood monitoring technology, which is currently undergoing clinical evaluations, as part of Inspira's goal to transform the mechanical ventilation market.

Inspira Technologies Deployment: Inspira Technologies has delivered its INSPIRA™ ART100 respiratory support systems to Glo-Med Networks for deployment in a leading U.S. hospital, aiming to enhance patient care with innovative life-support technology and direct support from their team.
Innovative Medical Technology: The INSPIRA™ ART100 system is designed to revolutionize cardiopulmonary bypass procedures and is set to be integrated with the HYLA™ blood monitoring technology, which is currently undergoing clinical evaluations, as part of Inspira's goal to transform the mechanical ventilation market.

New Leadership Appointment: Inspira Technologies has appointed Mr. Tal Parnes as the new chairman of the board, effective February 1, 2025, bringing over three decades of experience in medical technology and innovation to the role.
Company's Innovative Technology: The company is known for its groundbreaking Augmented Respiration Technology (INSPIRA™ ART), which aims to revolutionize mechanical ventilation by stabilizing oxygen levels without the need for a ventilator, enhancing patient care in intensive care units.

New Leadership Appointment: Inspira Technologies has appointed Mr. Tal Parnes as the new chairman of the board of directors, effective February 1, 2025, bringing over three decades of experience in the medical technology sector to enhance the company's leadership and strategic vision.
Innovative Medical Technology: The company is known for its groundbreaking Augmented Respiration Technology (INSPIRA™ ART), which aims to revolutionize mechanical ventilation by stabilizing oxygen levels in patients without the need for traditional ventilators, alongside other developing technologies like the HYLA™ blood sensor.

Inspira Technologies' Production Plans: Inspira Technologies is preparing for a potential increase in production of its INSPIRA™ ART100 respiratory device due to the recent outbreak of human metapneumovirus (hMPV) in China, indicating a growing global demand for advanced respiratory care technologies.
Innovative Medical Technology: The INSPIRA™ ART100 device aims to revolutionize mechanical ventilation by providing an alternative that stabilizes oxygen levels without requiring patients to be on ventilators, and has recently received FDA clearance for specific medical procedures.





